FDA Reaffirms Proteinuria Endpoint for FSGS: Positive Signal for Travere Therapeutics

FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in Travere Therapeutics' upcoming Filspari decision.